CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting
Abstract Bispecific antibodies (BsAbs) represent an innovative class of off-the-shelf T-cell redirecting agents and are considered among the most promising immunotherapeutic strategies for the treatment of lymphoma. Notably, anti-CD20 × CD3 BsAbs have exhibited substantial monotherapy efficacy in pa...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | https://doi.org/10.1186/s13045-025-01695-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849709590467313664 |
|---|---|
| author | V. Tomarchio L. Rigacci O. Annibali |
| author_facet | V. Tomarchio L. Rigacci O. Annibali |
| author_sort | V. Tomarchio |
| collection | DOAJ |
| description | Abstract Bispecific antibodies (BsAbs) represent an innovative class of off-the-shelf T-cell redirecting agents and are considered among the most promising immunotherapeutic strategies for the treatment of lymphoma. Notably, anti-CD20 × CD3 BsAbs have exhibited substantial monotherapy efficacy in patients with heavily pretreated B-cell non-Hodgkin lymphoma (B-NHL), showing a tolerable toxicity profile predominantly associated with T-cell activation-related side effects. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of Large B Cell Lymphoma (LBCL), also in first line, from the ASH 2024 annual meeting (ASH 2024). |
| format | Article |
| id | doaj-art-914d9f7da68b49d79ec67925d64b236a |
| institution | DOAJ |
| issn | 1756-8722 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj-art-914d9f7da68b49d79ec67925d64b236a2025-08-20T03:15:14ZengBMCJournal of Hematology & Oncology1756-87222025-04-011811410.1186/s13045-025-01695-1CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meetingV. Tomarchio0L. Rigacci1O. Annibali2Fondazione Policlinico Universitario Campus Bio-MedicoFondazione Policlinico Universitario Campus Bio-MedicoFondazione Policlinico Universitario Campus Bio-MedicoAbstract Bispecific antibodies (BsAbs) represent an innovative class of off-the-shelf T-cell redirecting agents and are considered among the most promising immunotherapeutic strategies for the treatment of lymphoma. Notably, anti-CD20 × CD3 BsAbs have exhibited substantial monotherapy efficacy in patients with heavily pretreated B-cell non-Hodgkin lymphoma (B-NHL), showing a tolerable toxicity profile predominantly associated with T-cell activation-related side effects. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of Large B Cell Lymphoma (LBCL), also in first line, from the ASH 2024 annual meeting (ASH 2024).https://doi.org/10.1186/s13045-025-01695-1 |
| spellingShingle | V. Tomarchio L. Rigacci O. Annibali CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting Journal of Hematology & Oncology |
| title | CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting |
| title_full | CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting |
| title_fullStr | CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting |
| title_full_unstemmed | CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting |
| title_short | CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting |
| title_sort | cd20 xcd3 bispecific antibodies for large b cell lymphoma latest updates from 2024 ash annual meeting |
| url | https://doi.org/10.1186/s13045-025-01695-1 |
| work_keys_str_mv | AT vtomarchio cd20xcd3bispecificantibodiesforlargebcelllymphomalatestupdatesfrom2024ashannualmeeting AT lrigacci cd20xcd3bispecificantibodiesforlargebcelllymphomalatestupdatesfrom2024ashannualmeeting AT oannibali cd20xcd3bispecificantibodiesforlargebcelllymphomalatestupdatesfrom2024ashannualmeeting |